Restless legs syndrome—current therapies and management of augmentation

被引:0
|
作者
Claudia Trenkwalder
Juliane Winkelmann
Yuichi Inoue
Walter Paulus
机构
[1] Paracelsus Elena Klinik,Department of Neurosurgery
[2] Centre of Parkinsonism and Movement Disorders,Department of Clinical Neurophysiology
[3] Kassel,Department of Neurology and Neurological Sciences and Centre for Sleep Sciences and Medicine
[4] University Medical Centre Göttingen,Department of Somnology
[5] University Medical Centre Göttingen,undefined
[6] Stanford University,undefined
[7] Neurologische Klinik und Poliklinik,undefined
[8] Klinikum rechts der Isar,undefined
[9] Technische Universität München,undefined
[10] Japan Somnology Center,undefined
[11] Neuropsychiatric Research Institute,undefined
[12] Tokyo Medical University,undefined
来源
Nature Reviews Neurology | 2015年 / 11卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Treatment of restless legs syndrome (RLS) usually involves dopamine agonists, which are approved for treatment of RLS in most countries; α-2-δ ligands, such as gabapentin enacarbil and pregabalin, are also effectiveIn patients with RLS who have low levels of ferritin, iron supplementation should be the first-line therapyFor patients with severe RLS, opioids such as oxycodone–naloxone are an option as second-line therapy where they are approvedAugmentation is a major complication of long-term RLS therapy with dopaminergic agents, and is related to high doses of dopaminergicsInternational treatment guidelines recommend weighing the benefits against the risks for each drug class when initiating treatmentCombined treatment approaches are used on the basis of expert opinions, and are currently not evidenced-based
引用
收藏
页码:434 / 445
页数:11
相关论文
共 50 条
  • [41] Socioeconomic impact of restless legs syndrome and inadequate restless legs syndrome management across European settings
    Trenkwalder, C.
    Tinelli, M.
    Sakkas, G. K.
    Dauvilliers, Y.
    Ferri, R.
    Rijsman, R.
    Oertel, W.
    Jaarsma, J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 (02) : 691 - 706
  • [42] Restless Legs Syndrome in the Older AdultDiagnosis and Management
    Shawn A. Milligan
    Andrew L. Chesson
    Drugs & Aging, 2002, 19 : 741 - 751
  • [43] Management of augmentatiion in patients with restless legs syndrome
    Trenkwalder, C
    Canelo, M
    SLEEP, 2005, 28 : A278 - A278
  • [44] Management of Restless Legs Syndrome in Patients on Dialysis
    Miklos Z. Molnar
    Marta Novak
    Istvan Mucsi
    Drugs, 2006, 66 : 607 - 624
  • [45] Diagnosis and management of restless legs syndrome in children
    Simakajornboon, Narong
    Kheirandish-Gozal, Leila
    Gozal, David
    SLEEP MEDICINE REVIEWS, 2009, 13 (02) : 149 - 156
  • [46] Polysomnographic record and successful management of augmentation in restless legs syndrome/Willis-Ekbom disease
    Maestri, Michelangelo
    Fulda, Stephany
    Ferini-Strambi, Luigi
    Zucconi, Marco
    Marelli, Sara
    Staedler, Claudio
    Bassetti, Claudio L.
    Manconi, Mauro
    SLEEP MEDICINE, 2014, 15 (05) : 570 - 575
  • [47] PTPRD as a candidate druggable target for therapies for restless legs syndrome?
    Morais, Milca A.
    Franco, Beatriz
    Holanda, Alessandro S. S.
    Simino, Lais Angelica de Paula
    Manconi, Mauro
    Torsoni, Adriana
    Esteves, Andrea M.
    JOURNAL OF SLEEP RESEARCH, 2021, 30 (04)
  • [48] Management of restless legs syndrome in patients on dialysis
    Molnar, Miklos Z.
    Novak, Marta
    Mucsi, Istvan
    DRUGS, 2006, 66 (05) : 607 - 624
  • [49] New concepts in the management of restless legs syndrome
    Garcia-Borreguero, Diego
    Cano-Pumarega, Irene
    BMJ-BRITISH MEDICAL JOURNAL, 2017, 356
  • [50] Pharmacological management of childhood restless legs syndrome
    Sayed, MA
    Kotagal, P
    Foldvary, N
    Bae, C
    SLEEP, 2005, 28 : A83 - A83